WEINBERG MEDICAL PHYSICS, INC. — Department of Health and Human Services STTR Phase I: 102

WEINBERG MEDICAL PHYSICS, INC. — STTR Phase I award from Department of Health and Human Services.

Amount
$142,262
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
STTR · Phase I
Topic
102
Solicitation
PA16-303
NAICS
Place of performance
MD
Period
2017-06-01 → 2019-05-31

Description

Abstract Glioblastoma multiforme GBM is the deadliest form of brain tumor The current treatment includes a combination of surgical resection chemotherapy radiation and electrical disruption of mitosis has only extended survival to approximately to years Preliminary pre clinical findings suggest the potential effectiveness of the candidate drug cyclopamine However the drug is toxic to systemic stem cells when given intravenously and at high concentrations in the nervous system may cause toxicity to astrocytes Furthermore poor solubility has precluded effective transport of drug to tumor in the central nervous system The Molecular Neurosurgery Laboratory led by the STTR PI neurosurgeon Dr Steven Toms at the Geisinger Medical Center has expertise in nanoparticulate delivery to brain tumors and has developed a human glioblastoma stem cell derived xenograft model for in vitro and in vivo testing of therapies for GBM STTR applicant Weinberg Medical Physics LLC has developed a new method of transporting drug across the blood brain barrier directly to target sites within the brain This approach accesses the brain via administration of magnetically propelled nanoparticles into the cranium with magnetic focusing of the drug laden nanoparticles in a novel combined MR imaging magnetic focusing apparatus In this proposal we will demonstrate the safety and efficacy of drug delivery of the magnetic nanoparticle cyclopamine construct using the MR imaging magnetic focusing apparatus by measuring cyclopamine drug concentrations in animal tissues In addition we will confirm that there are no neuropathological changes to the animals as a result of the magnetic propulsion process and demonstrate that this method of drug delivery improves survival in rodent GBM xenograft models The results of this collaborative work will lay the foundation for Phase II studies that will collect information needed for clinical trials STTR applicant Weinberg Medical Physics LLC has developed a new method of transporting drug across the blood brain barrier directly to target sites within the brain This approach accesses the brain via trans nasal administration of magnetically propelled nanoparticles and then magnetically focuses the drug laden nanoparticles in a novel combined MR imaging magnetic focusing apparatus In this proposal we will demonstrate the safety and efficacy of drug delivery of the magnetic nanoparticle cyclopamine construct using the MR imaging magnetic focusing apparatus by measuring cyclopamine drug concentrations in animal tissues